

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.SciCrunch.org) on Apr 13, 2025

## PD1 antibody [NAT]

RRID:AB\_881954

Type: Antibody

---

### Proper Citation

(Abcam Cat# ab52587, RRID:AB\_881954)

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_881954](http://antibodyregistry.org/AB_881954)

**Proper Citation:** (Abcam Cat# ab52587, RRID:AB\_881954)

**Target Antigen:** TY cells (human T/NK cell Leukemia)

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Used By NYUIHC-835

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:TRUE, Functional in animal:FALSE, NonFunctional in animal:FALSE

**Antibody Name:** PD1 antibody [NAT]

**Description:** This monoclonal targets TY cells (human T/NK cell Leukemia)

**Target Organism:** human

**Clone ID:** [NAT]

**Antibody ID:** AB\_881954

**Vendor:** Abcam

**Catalog Number:** ab52587

**Record Creation Time:** 20241017T002609+0000

**Record Last Update:** 20241017T021116+0000

---

## Ratings and Alerts

- Independent validation by the NYU Langone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:TRUE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development  
<https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for PD1 antibody [NAT].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 19 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Martins C, et al. (2024) Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling. *Science advances*, 10(3), eadi2012.

Wang B, et al. (2024) Glycolysis Induced by METTL14 Is Essential for Macrophage Phagocytosis and Phenotype in Cervical Cancer. *Journal of immunology (Baltimore, Md. : 1950)*, 212(4), 723.

Zhang J, et al. (2024) Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor. *Cell*, 187(13), 3409.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. *Cell reports. Medicine*, 5(2), 101397.

Bao X, et al. (2024) A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer. *Cell reports. Medicine*, 5(2), 101399.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. *Cancer cell*.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Johnson BE, et al. (2022) An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. *Cell reports. Medicine*, 3(2), 100525.

Wen J, et al. (2022) Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. *EBioMedicine*, 86, 104371.

Meylan M, et al. (2022) Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. *Immunity*, 55(3), 527.

Ducoin K, et al. (2022) Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy. *Cancers*, 14(17).

Wheeler DA, et al. (2021) Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. *Cancer cell*, 39(1), 38.

Au L, et al. (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. *Cancer cell*, 39(11), 1497.

Hornburg M, et al. (2021) Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer cell*, 39(7), 928.

Maynard A, et al. (2020) Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. *Cell*, 182(5), 1232.

Salvador-Barbero B, et al. (2020) CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. *Cancer cell*, 37(3), 340.

León-Letelier RA, et al. (2020) Induction of Progenitor Exhausted Tissue-Resident Memory CD8+ T Cells Upon Salmonella Typhi Porins Adjuvant Immunization Correlates With Melanoma Control and Anti-PD-1 Immunotherapy Cooperation. *Frontiers in immunology*, 11, 583382.

Toulmonde M, et al. (2020) High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies. *EBioMedicine*, 62, 103131.

Kather JN, et al. (2018) Topography of cancer-associated immune cells in human solid tumors. *eLife*, 7.